Pomegranate - Evista (Raloxifene) Interaction
Herbal: Pomegranate
Also Known As: Punica granatum, Anardana, Dadim, Dadima, Delima, Extrait de Feuille de Grenade, Extrait de Grenade, Extrait de Polyphénol de Grenade, Feuille de Grenade, Fleur de Grenade, Fruit du Grenadier, Fruit of the Dead, Gangsalan, Granaatappel, Granad, Granada, Granado
Drug: Raloxifene
Brand names:
Evista

Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Jun 15, 2025
Interaction Details
There were no interactions found between Raloxifene and Pomegranate. This does not mean the potential for an interaction does not exist, however. There is often a lack of studies and data surrounding traditional medicine, especially concerning drug interactions, so it is important to always consult your provider before making any changes to your medication regimen.
Pharmacist Analysis
Pomegranate (and pomegranate extract) has several potential drug interactions that should be taken into consideration.
Primarily, pomegranate can affect drugs metabolized by CYP2C9, CYP2D6, and CYP3A4 enzymes. This accounts for a very large proportion of the drug interactions associated with pomegranate.
Pomegranate also may have mild antihypertensive effects, potentially increasing the risk of adverse effects and hypotension when used with other drugs that lower blood pressure.
Although there is no interaction noted between pomegranate and the drug in question, as always, it is recommended to speak with your doctor before adding on any new medications or supplements so you can be appropraitely monitored.
- Dr. Brian Staiger, PharmDPomegranate Overview

Raloxifene Overview
-
Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in postmenopausal (women who have experienced a change of life; end of menstrual periods) women. Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in postmenopausal women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition. Raloxifene also cannot be used to decrease the risk of developing noninvasive breast cancer. Raloxifene should not be used in women who have not yet experienced menopause. Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.
Pomegranate - More Interactions
Pomegranate interacts with 898 drugs
Interaction Rating Key
These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.
Major | The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur. |
Moderate | Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur. |
Minor | Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction. |
Unknown | No interactions have been reported or no interaction data is currently available. |
Return to the main supplement interaction checker page
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Drug descriptions are provided by MedlinePlus.